41 Recruiting Studies Using Epcoritamab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Epcoritamab
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
📍 The University of Arizona Cancer Center - North Campus /ID# 242219 — Tucson, Arizona
Non-Hodgkin Lymphoma
View Study & Checklist ➔A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
📍 University of Arizona Cancer Center - North Campus /ID# 227463 — Tucson, Arizona
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
📍 City of Hope National Medical Center /ID# 273338 — Duarte, California
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
📍 University of Alabama at Birmingham — Birmingham, Alabama
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
📍 Infirmary Health - Infirmary Cancer Care at Mobile Infirmary /ID# 264630 — Mobile, Alabama
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
📍 UCSF Fresno /ID# 264712 — Fresno, California
Follicular Lymphoma (FL)
View Study & Checklist ➔First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
📍 Arizona Mayo Clinic — Phoenix, Arizona
DLBCL
View Study & Checklist ➔A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
📍 Indiana Blood and Marrow Transplantation — Indianapolis, Indiana
Diffuse Large B-cell Lymphoma
View Study & Checklist ➔Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
📍 O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham — Birmingham, Alabama
Relapsed/Refractory Chronic Lymphocytic Leukemia
View Study & Checklist ➔Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
📍 The University of Arizona Cancer Center - North Campus /ID# 228862 — Tucson, Arizona
Follicular Lymphoma (FL)
View Study & Checklist ➔Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
📍 City of Hope Medical Center — Duarte, California
Follicular Lymphoma
View Study & Checklist ➔Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Leukemia, Chronic Lymphocytic
View Study & Checklist ➔Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
📍 Lucile Packard Children's Hospital /ID# 240854 — Palo Alto, California
Non-hodgkin Lymphoma
View Study & Checklist ➔Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
📍 UT MD Anderson Cancer Center — Houston, Texas
Randomized
View Study & Checklist ➔Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study
📍 Memorial Sloan Kettering Cancer Center — New York, New York
Adult Burkitt Lymphoma
View Study & Checklist ➔Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
📍 Zuckerberg San Francisco General — San Francisco, California
Non-Hodgkin's B-cell Lymphoma
View Study & Checklist ➔Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
📍 University of Cincinnati — Cincinnati, Ohio
CLL/SLL
View Study & Checklist ➔Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
View Study & Checklist ➔A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
📍 Mayo Clinic in Arizona - Phoenix — Phoenix, Arizona
Relapsed/Refractory Non-Hodgkin Lymphoma
View Study & Checklist ➔Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
B-Cell Non-Hodgkin Lymphoma
View Study & Checklist ➔Epcoritamab in Previously Treated WM
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
Waldenstrom Macroglobulinemia
View Study & Checklist ➔Low Dose Epcoritamab Plus GemOx in R/R DLBCL
📍 Hospital Universitario "Dr. José Eleuterio González" — Monterrey, Nuevo León
Relapsed/Refractory Diffuse Large B Cell Lymphoma
View Study & Checklist ➔Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
📍 Stanford — Stanford, California
Lymphoma
View Study & Checklist ➔Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
📍 Northwestern University — Chicago, Illinois
Recurrent B-Cell Non-Hodgkin Lymphoma
View Study & Checklist ➔Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
📍 City of Hope Medical Center — Duarte, California
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
View Study & Checklist ➔Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
📍 University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
Recurrent Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
📍 University of Miami — Miami, Florida
Large B-cell Lymphoma
View Study & Checklist ➔A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Primary Central Nervous System Lymphoma (PCNSL)
View Study & Checklist ➔External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
📍 Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Diffuse Large B Cell Lymphoma
View Study & Checklist ➔Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
📍 City of Hope Medical Center — Duarte, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Epcoritamab-CAR T Cells for Large B-cell Lymphomas
📍 Abramson Cancer Center at the University of Pennsylvania — Philadelphia, Pennsylvania
Lymphoma, Non-Hodgkin
View Study & Checklist ➔Epco, Zanu, Ritux for R/R FL or MZL
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Follicular Lymphoma
View Study & Checklist ➔Outpatient Epcoritamab in Large B-cell Lymphoma
📍 Massachusetts General Hospital — Boston, Massachusetts
Relapsed Large B-cell Lymphoma
View Study & Checklist ➔Epcoritamab and Rituximab for First-line Follicular Lymphoma
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
Follicular Lymphoma
View Study & Checklist ➔Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
📍 University of Miami — Miami, Florida
Marginal Zone Lymphoma
View Study & Checklist ➔Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
📍 Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center — Cleveland, Ohio
Non-Hodgkin Lymphoma
View Study & Checklist ➔Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
📍 Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
Large Cell Lymphoma, Diffuse
View Study & Checklist ➔Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
Large B-cell Lymphoma
View Study & Checklist ➔Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
📍 Washington University — St Louis, Missouri
Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder
View Study & Checklist ➔Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
Recurrent Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔